Angela Pires Brandao

Dr. Angela Pires Brandao

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2021 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
Juliana Maira Watanabe PinhataJuliana Maira Watanabe Pinhata
Juliana Maira Watanabe Pinhata
ABAngela Pires Brandao
Angela Pires Brandao
FMFlávia de Freitas Mendes
Flávia de Freitas Mendes
MRMichelle Christiane da Silva Rabello
Michelle Christiane da Silva Rabello
LFLucilaine Ferrazoli
Lucilaine Ferrazoli
RORosângela Siqueira de Oliveira
Rosângela Siqueira de Oliveira

1 December 2020 in Tuberculosis
Verified
Journal Article
Closed access
ABAngela Pires Brandao
Angela Pires Brandao
Juliana Maira Watanabe PinhataJuliana Maira Watanabe Pinhata
Juliana Maira Watanabe Pinhata
VSVera Simonsen
Vera Simonsen
RORosangela Siqueira Oliveira
Rosangela Siqueira Oliveira
KGKelen Teixeira Ghisi
Kelen Teixeira Ghisi
LFLucilaine Ferrazoli
Lucilaine Ferrazoli

1 January 2019 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
PDF file
ABAngela Pires Brandao
Angela Pires Brandao
Juliana Maira Watanabe PinhataJuliana Maira Watanabe Pinhata
Juliana Maira Watanabe Pinhata
RORosangela Siqueira Oliveira
Rosangela Siqueira Oliveira
VGVera Maria Neder Galesi
Vera Maria Neder Galesi
HCHelio Hehl Caiaffa-Filho
Helio Hehl Caiaffa-Filho
LFLucilaine Ferrazoli
Lucilaine Ferrazoli
Objective: To evaluate the rapid diagnosis of multidrug-resistant tuberculosis, by using a commercial line probe assay for rifampicin and isoniazid detection (LPA-plus), in the routine workflow of a tuberculosis reference laboratory. Methods: The LPA-plus was prospectively evaluated on 341 isolates concurrently submitted to the automated liquid drug susceptibility testing system. Results: Among 303 phenotypically valid results, none was genotypically rifampicin false-susceptible (13/13; 100% sensitivity). Two rifampicin-susceptible isolates harboured rpoB mutations (288/290; 99.3% specificity) which, however, were non-resistance-conferring mutations. LPA-plus missed three isoniazid-resistant isolates (23/26; 88.5% sensitivity) and detected all isoniazid-susceptible isolates (277/277; 100% specificity). Among the 38 (11%) invalid phenotypic results, LPA-plus identified 31 rifampicin- and isoniazid-susceptible isolates, one isoniazid-resistant and six as non-Mycobacterium tuberculosis complex. Conclusions: LPA-plus showed excellent agreement (≥91%) and accuracy (≥99%). Implementing LPA-plus in our setting can speed up the diagnosis of multidrug-resistant tuberculosis, yield a significantly higher number of valid results than phenotypic drug susceptibility testing and provide further information on the drug-resistance level.

1 January 2020 in Access Microbiology
Verified
Journal Article
Open access
MGMaria Cecília Gorla
Maria Cecília Gorla
ABAngela Pires Brandao
Angela Pires Brandao
Juliana Maira Watanabe PinhataJuliana Maira Watanabe Pinhata
Juliana Maira Watanabe Pinhata
CMCamile de Moraes
Camile de Moraes
GPGabriela Pereira
Gabriela Pereira
ALAna Paula Lemos
Ana Paula Lemos
Introduction . Invasive meningococcal disease (IMD) has a high rate of fatality and may cause severe clinical sequelae. Over the years, the epidemiology of IMD has changed significantly in various regions of the world, and laboratory surveillance of this disease is important for mapping epidemiologic changes. Aim. To perform phenotypic characterization of Neisseria meningitidis strains isolated from invasive disease in Brazil from 2002 to 2017, as a complementation of the data obtained in the period of 1990–2001. Methodology . In total, 8,689 isolates sent to Adolfo Lutz Institute confirmed as N. meningitidis by conventional methods were serogrouped by slide agglutination against MenA, MenB, MenC, MenE, MenW, MenX, MenY and MenZ; serotyped and serosubtyped by a whole-cell dot-blotting assay with monoclonal antibodies. Results . The isolates were sent from all regions of Brazil, and the southeast region was responsible for the largest number of isolates (57.2 %). Overall, the total sample (n=8,689) was represented by serogroups C (n=4,729; 54.4 %), B (n=3,313; 38.1 %), W (n=423; 4.9 %), Y (n=203; 2.3 %), X (n=5; 0.1 %) and others (n=16; 0.2 %). A shift in the prevalence of serogroups was observed in 2006, when serogroup C became the most prevalent (65.5 %), surpassing the serogroup B (21.9 %). The main isolated phenotypes were C:23:P1.14–6; B:4,7:P1.19,15; W:2a:P1.5 and W:2a:P1.5,2. Conclusion . The data show an important change in the distribution of meningococcal serogroups, serotypes and subtypes occurring during 2002–2017. A continuous laboratory-based surveillance provides robust information to implement appropriate strategies to IMD control.

29 October 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
RORosângela Siqueira Oliveira
Rosângela Siqueira Oliveira
ABAngela Pires Brandao
Angela Pires Brandao
FFFabiane Maria de Almeida Ferreira
Fabiane Maria de Almeida Ferreira
SCSonia Maria da Costa
Sonia Maria da Costa
VSVera Lucia Maria Silva
Vera Lucia Maria Silva
Juliana Maira Watanabe PinhataJuliana Maira Watanabe Pinhata
Juliana Maira Watanabe Pinhata
Drug-resistant tuberculosis (DR-TB) threatens global TB control. We investigated the prevalence and molecular characteristics of second-line drug resistance among rifampicin (RIF)- and/or isoniazid (INH)-resistant Mycobacterium tuberculosis complex (MTBC) isolates in São Paulo, Brazil, using the MTBDRsl v. 2.0 line-probe assay. MTBC isolates RIF- and/or INH-resistant by GenoType MTBDRplus or phenotypic testing (2019–2021) were subsequently tested by MTBDRsl for fluoroquinolone (FQ) and injectable drugs (capreomycin, amikacin, kanamycin) resistance. Isolates with inferred mutations underwent Sanger sequencing. Of 13,557 isolates, 728 (5.4%) were RIF- and/or INH-resistant (297 INH-R, 235 RIF-R, 196 MDR). Among them, 623 (85.6%) were tested by MTBDRsl; 582 (93.4%) showed no additional resistance, while 41 (6.6%) carried mutations. FQ resistance was detected in 38 isolates (92.7%), mostly in gyrA (n = 35). Three isolates with gyrB mutations were wild-type by sequencing. Two MDR isolates harbored the rrs a1401g mutation, and one also harbored gyrA D94G. Sequencing confirmed resistance in 38 of 41 isolates. Most MDR strains with second-line mutations (n = 32/33; 97%) were pre-XDR. Affected patients were predominantly male (68.4%), with pulmonary TB (92.1%), and unfavorable outcomes (39.5%). Second-line resistance prevalence was low overall, but FQ resistance was high among MDR isolates. Findings support integrating molecular and sequencing-based tools for accurate detection and management of DR-TB.

1 January 2025 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
RORosângela Siqueira de Oliveira
Rosângela Siqueira de Oliveira
ABAngela Pires Brandao
Angela Pires Brandao
FFFabiane Maria de Almeida Ferreira
Fabiane Maria de Almeida Ferreira
SCSonia Maria da Costa
Sonia Maria da Costa
VSVera Lucia Maria da Silva
Vera Lucia Maria da Silva
Juliana Maira Watanabe PinhataJuliana Maira Watanabe Pinhata
Juliana Maira Watanabe Pinhata
Background: In this study, we aimed to describe the mutations associated with first-line drug resistance in Mycobacterium tuberculosis complex (MTBC) isolates from São Paulo, Brazil, between 2019 and 2021. Methods: Mutations in the coding regions of rpoB and katG genes and in the promoter region of the inhA gene in MTBC clinical isolates were detected using the GenoType MTBDRplus assay (LPA). All mutations inferred by LPA were sequenced. Results: Of the 13,489 MTBC isolates with valid LPA results, 657 (4.9%) harbored mutations. The overall prevalence rates of rifampicin-resistant (RIF-R) tuberculosis (TB), isoniazid-resistant (INH-R) TB, and multidrug-resistant (MDR) TB were 1.5, 2.0, and 1.2%, respectively. A significant proportion of RIF-R isolates presented inferred rpoB mutations (89.1%), most of which were the borderline H445N mutation. The inhA promoter C-15T mutation was predominant among the INH-R isolates (52.8%). Most MDR isolates presented rpoB S450L + katG S315T1 mutations. Gene sequencing identified mutations not included in the catalogue of mutations published by the World Health Organization. Phenotypic drug susceptibility testing on isolates with inferred rpoB mutations revealed that the 0.5 µg/mL critical concentration of RIF failed to detect most borderline mutations when using the BACTEC MGIT 960 system. Conclusions: These findings emphasize the need for continuous surveillance and the integration of molecular and phenotypic methods to ensure an accurate detection and management of drug-resistant TB in high-burden settings.